Eisai Satisfies All-Case Surveillance Requirement for Anticancer Agent Remitoro
TOKYO, May 16, 2025 – (JCN Newswire via SeaPRwire.com) – Eisai Co., Ltd. announced today that it has received notification from Japan’s Ministry of Health, Labour, and Welfare (MHLW) that the “all-case surveillance” post-marketing observational study condition required at the time of approval of anticancer agent “Remitoro® for Intravenous Drip Infusion 300μg” (Denileukin Diftitox (Genetical […]